Overexpressing signaling downstream components, such as c-Jun, prolongs CAR-T-cell persistence, reduces exhaustion and improves antitumor potency [104], an approach under clinical evaluation in acute myeloid leukemia (AML) (NCT04835519) [105]. Here, JUN is linked to acute myeloid leukemia.